// App-Quantinova.ai

: Tafasitamab Plus Lenalidomide Versus Pola-BR, R2, and CAR T: Comparing Outcomes from RE-MIND2, an Observational, Retrospective Cohort Study in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Researchers

Presenter

  • Grzegorz S. Nowakowski

Principal Investigators

  • Patrizia Mondello

  • Erel Joffe

  • Isabelle Fleury

  • Anthea Peters

  • Richard Greil

  • Matthew Ku

  • Reinhard Marks

  • Kibum Kim

  • Pier Luigi Luigi Zinzani

  • Judith Trotman

  • Lorenzo Sabatelli

  • Dan Huang

  • Eva E. Waltl

  • Mark Winderlich

  • Sumeet Ambarkhane

  • Nuwan C. Kurukulasuriya

  • Raul Cordoba

  • Georg Hess

  • Gilles Salles

Medical Centers

  • Department of Oncology, University of Alberta, Edmonton, Canada

  • Paracelsus Medical University Salzburg, Salzburg Cancer Research Institute-CCCIT, and Cancer Cluster Salzburg, Salzburg, Austria

  • University Hospital Freiburg Internal Medicine I, Freiburg im Breisgau, Germany

  • Department of Medicine, Memorial Sloan Kettering Cancer Center, Rochester, NY

  • University of Utah, Salt Late City, UT

  • MorphoSys AG, Boston, MA

  • Memorial Sloan Kettering Cancer Center, New York, NY

  • Incyte Biosciences International Sàrl, Morges, Switzerland

  • Department of Oncology, Asan Medical Center, Seoul, Korea, Republic of (South)

  • MorphoSys AG, Planegg, Germany

  • Division of Hematology, Mayo Clinic, ROCHESTER, MN

  • Fundacion Jimenez Diaz University Hospital, Madrid, Spain

  • Department of Hematology, Oncology and Pneumology, University Medical Center, Johannes Gutenberg-University Mainz, Mainz, Germany

  • Department of Haematology, St Vincent's Hospital and University of Melbourne, Melbourne, Australia

  • Maisonneuve-Rosemont Hospital, Institute of Hematology, Oncology and Cell Therapy, Montreal University, Montreal, Canada

  • Haematology Department, Concord Repatriation General Hospital, University of Sydney, Concord, Australia

Locations

  • Canada

  • Republic of South Korea

  • Austria

  • Germany

  • United States

  • Spain

  • Australia

  • Switzerland

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Diffuse large B-cell lymphoma

Biomarkers

  • Coxsackie Virus And Adenovirus Receptor

Drug/Treatment

  • Lenalidomide

  • Tafasitamab

Outcome

  • N/A

Study Design

  • Observational

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved